Developmental Pharmacogenetics: A General Paradigm for Application to Neonatal Pharmacology and ToxicologyLEEDER, J. S.Clinical pharmacology and therapeutics. 2009, Vol 86, Num 6, pp 678-682, issn 0009-9236, 5 p.Article

Special Patient Populations : Developmental aspects of drug metabolism in children : Drug development for infants and children : Rescuing the therapeutic orphanLEEDER, J. S.Drug information journal. 1996, Vol 30, Num 4, pp 1135-1143, issn 0092-8615Conference Paper

Mechanisms of idiosyncratic Hypersensitivity reactions to antiepileptic drugsLEEDER, J. S.Epilepsia (Copenhagen). 1998, Vol 39, pp S8-S16, issn 0013-9580, SUP7Conference Paper

Application of pharmacogenomic strategies to the study of drug-induced birth defectsLEEDER, J. S; MITCHELL, A. A.Clinical pharmacology and therapeutics. 2007, Vol 81, Num 4, pp 595-599, issn 0009-9236, 5 p.Article

Glucagon therapy for β-blocker overdosePETERSON, C. D; LEEDER, J. S; STERNER, S et al.Drug intelligence & clinical pharmacy. 1984, Vol 18, Num 5, pp 394-398, issn 0012-6578Article

Drug metabolism for the paediatricianDE WILDT, Saskia N; TIBBOEL, D; LEEDER, J. S et al.Archives of disease in childhood. 2014, Vol 99, Num 12, pp 1137-1142, issn 0003-9888, 6 p.Article

The challenges of delivering pharmacogenomics into clinical pediatricsLEEDER, J. S; KEARNS, G. L.Pharmacogenomics journal (Print). 2002, Vol 2, Num 3, pp 141-143, issn 1470-269XArticle

In vitro analysis of metabolic predisposition to drug hypersensitivity reactionsRILEY, R. J; LEEDER, J. S.Clinical and experimental immunology (Print). 1995, Vol 99, Num 1, pp 1-6, issn 0009-9104Article

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitorMEYDAN, N; GRUNBERGER, T; LEVITZKI, A et al.Nature (London). 1996, Vol 379, Num 6566, pp 645-648, issn 0028-0836Article

Cytochromes P450 and liver injuryLEEDER, J. S; OKEY, A. B.Handbook of experimental pharmacology. 1996, Vol 121, pp 119-153, issn 0171-2004Article

Expression and inducibility of antigens in severe combined immunodeficient mice recognized by human anti-P450 antibodiesRAJASENAN, R. S; RILEY, R. J; LEEDER, J. S et al.Toxicology and applied pharmacology. 1995, Vol 135, Num 1, pp 89-99, issn 0041-008XArticle

Safety of lidocaine-prilocaine cream in the treatment of preterm neonatesTADDIO, A; SHENNAN, A. T; STEVENS, B et al.The Journal of pediatrics. 1995, Vol 127, Num 6, pp 1002-1005, issn 0022-3476Article

Fluorescence-based viability assay for studies of reactive drug intermediatesLEEDER, J. S; DOSCH, H.-M; HARPER, P. A et al.Analytical biochemistry. 1989, Vol 177, Num 2, pp 364-372, issn 0003-2697Article

High-pressure liquid chromatographic analysis of ceftazidime in serum and urineLEEDER, J. S; SPINO, M; TESORO, A. M et al.Antimicrobial agents and chemotherapy. 1983, Vol 24, Num 5, pp 720-724, issn 0066-4804Article

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and CodeineTherapy: 2014 UpdateCREWS, K. R; GAEDIGK, A; PROWS, C. A et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 4, pp 376-382, issn 0009-9236, 7 p.Article

Concordance between tramadol and dextromethorphan parent/metabolite ratios: The influence of CYP2D6 and non-CYP2D6 pathways on biotransformationABDEL-RAHMAN, S. M; LEEDER, J. S; WILSON, J. T et al.Journal of clinical pharmacology. 2002, Vol 42, Num 1, pp 24-29, issn 0091-2700Article

Acetaminophen intoxication during treatment : What you don't know can hurt youKEARNS, G. L; LEEDER, J. S; WASSERMAN, G. S et al.Clinical pediatrics. 2000, Vol 39, Num 3, pp 133-144, issn 0009-9228Article

Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafineABDEL-RAHMAN, S. M; MARCUCCI, K; BOGE, T et al.Drug metabolism and disposition. 1999, Vol 27, Num 7, pp 770-775, issn 0090-9556Article

Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactionsLEEDER, J. S; XIAOLI LU; TIMSIT, Y et al.Pharmacogenetics (London). 1998, Vol 8, Num 3, pp 211-225, issn 0960-314XArticle

Reversion of the SCID phenotype by human T cell grafts : development of cross-species immunocompetenceDONJON, C. M; MORKOWSKI, H; CHEUNG, R. K et al.The Journal of immunology (1950). 1993, Vol 151, Num 11, pp 5948-5954, issn 0022-1767Article

Limitations of dextromethorphan N-demethylation as a measure of CYP3A activityKASHUBA, A. D. M; NAFZIGER, A. N; KEARNS, G. L et al.Pharmacogenetics (London). 1999, Vol 9, Num 4, pp 453-462, issn 0960-314XArticle

Glucuronidation in humans : Pharmacogenetic and developmental aspectsDE WILDT, S. N; KEARNS, G. L; LEEDER, J. S et al.Clinical pharmacokinetics. 1999, Vol 36, Num 6, pp 439-452, issn 0312-5963Article

Human anti-endoplasmic reticulum autoantibidodies produced in aromatic anticonvulsant hypersensitivity reactions recognise rodent CYP3A proteins and a similarly regulated human P450 enzyme(s)RILEY, R. J; SMITH, G; WOLF, C. R et al.Biochemical and biophysical research communications (Print). 1993, Vol 191, Num 1, pp 32-40, issn 0006-291XArticle

Cellular toxicity of sulfamethoxazole reactive metabolites. II, Inhibition of natural killer activity in human peripheral blood mononuclear cellsLEEDER, J. S; NAKHOODA, A; SPIELBERG, S. P et al.Biochemical pharmacology. 1991, Vol 41, Num 4, pp 575-583, issn 0006-2952, 9 p.Article

Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione : implications for idosyncratic toxicityCRIBB, A. E; MILLER, M; LEEDER, J. S et al.Drug metabolism and disposition. 1991, Vol 19, Num 5, pp 900-906, issn 0090-9556Article